C
Cogentix Medical
A global medical device company that develops, manufactures, and markets products for the minimally invasive treatment of voiding dysfunctions and endoscopy solutions
About Cogentix Medical
The story of Cogentix Medical isn’t one of a typical startup, but a strategic combination of two existing med-tech players. In March 2015, Minnesota-based Uroplasty and New York's Vision-Sciences, founded by Lewis Pell, merged to form Cogentix Medical. The new entity, led by Uroplasty’s CEO Rob Kill, was established to diagnose and treat urologic conditions, combining Uroplasty’s devices for overactive bladder and incontinence with Vision-Sciences’ endoscopy systems. The goal was to create a larger, more robust company in the urology space. The newly formed Cogentix focused on key products like the Urgent PC Neuromodulation System, a non-drug treatment for overactive bladder, and the PrimeSight endoscopy line which utilized a sterile disposable barrier to improve safety and efficiency. However, the initial years following the merger were challenging, leading to a crucial turning point in 2016. A $25 million private equity investment from Accelmed and the conversion of debt held by co-founder Lewis Pell into equity were instrumental in keeping the company afloat and positioning it for future growth. This strategic reset paid off. By 2018, Cogentix Medical had become an attractive target. Laborie Medical Technologies, a Canadian company owned by the Swedish investment firm Investor AB, announced its intent to acquire Cogentix. The acquisition was finalized in April 2018 for approximately $214 million. This move integrated Cogentix's therapeutic devices into Laborie's broader urology portfolio, providing a comprehensive set of solutions from diagnosis to treatment. Following the acquisition, Cogentix Medical was delisted from the Nasdaq stock market, marking the end of its journey as an independent public company and its absorption into a larger global entity.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2018 | $239M | $239M | Undisclosed | — |
| GROWTH EQUITY VC✓Equity / VC | Sep 2016 | $25M | — | Accelmed | — |
Growth signals
Latest recorded traffic for Cogentix Medical is 12K monthly website visits, up 242.9% over the last three months. Cogentix Medical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vensica MedicalIsraelA medical device company that is designing and developing and Ultrasound catheter for the treatment of bladder cancer
$80Mvaluation
GM
Genesis MedicalLondon, United KingdomGenesis Medical produces, sells and markets urology products
→
UroplastyMinnetonka, United StatesGlobal medical company committed to offering transformative treatment options through specialty physicians
→
Vision SciencesOrangeburg, United StatesFlexible endoscopes as a control solution to decrease the risk of cross-contamination
→
Cogentix Medical in the Minnetonka ecosystem
The Cogentix Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Accelmed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cogentix Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cogentix Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







